20/20 Biolabs Eyes Nasdaq Direct Listing with AI-Powered Cancer Test

TL;DR

**AIDX's direct listing is a high-stakes bet on affordable AI-powered cancer screening, offering disruptive potential but also significant market volatility risk.**

AI Summary

20/20 Biolabs, Inc. (AIDX) is pursuing a direct listing on Nasdaq, registering 15,130,055 shares for resale by existing stockholders. The company develops and commercializes AI-powered, laboratory-based blood tests for early cancer and chronic disease detection, primarily through its OneTest brand. For the nine months ended September 30, 2025, OneTest for Cancer accounted for approximately 87% of revenues, BioCheck for 9%, and CLIAx for 4%. In 2024, OneTest for Cancer represented 85% of revenues, up from 65% in 2023, while COVID-19 testing revenue declined from 18% in 2023 to 0% in 2024. The company's flagship product, OneTest for Cancer, is a multi-cancer early detection (MCED) blood test utilizing protein tumor markers (PTMs) and AI, priced under $200, and demonstrated in 2024 NCI studies to identify early-stage cancers. A new product, OneTest for Longevity, measuring inflammatory biomarkers, is expected to launch in the first half of 2026. The company operates a CAP-accredited, CLIA-licensed laboratory in Gaithersburg, MD, which also hosts its CLIAx accelerator.

Why It Matters

This direct listing offers investors a chance to participate in the burgeoning multi-cancer early detection market, a sector with significant growth potential. 20/20 Biolabs' strategy of using affordable, accessible protein tumor markers (PTMs) for its OneTest for Cancer positions it as a potential disruptor against more expensive ctDNA-based competitors like Grail's Galleri. Success could mean earlier cancer detection for patients, reduced healthcare costs, and a significant market share for AIDX, but the novelty of a direct listing without an underwriter introduces unique price volatility risks for early investors. The company's CLIAx accelerator also provides a unique revenue stream and potential for future diagnostic innovations.

Risk Assessment

Risk Level: high — The S-1 filing explicitly states, "Investing in our securities involves a high degree of risk." The direct listing mechanism itself is a novel method for commencing public trading, which could lead to more volatile trading volume and price than a firm-commitment underwritten offering. Furthermore, the company is an 'emerging growth company' and relies heavily on its OneTest for Cancer, which, while showing promise in NCI studies, operates in a competitive and rapidly evolving diagnostic market.

Analyst Insight

Investors should approach AIDX with caution, recognizing the high risk associated with its direct listing and the competitive landscape of cancer diagnostics. While the company's PTM-based approach offers a potentially more affordable and accessible solution, investors should thoroughly evaluate the 'Risk Factors' section starting on page 13 and monitor initial trading volatility closely before considering an investment.

Revenue Breakdown

Key Numbers

• $200 — Starting price of OneTest for Cancer (Positions OneTest as an affordable multi-cancer early detection test)
• 15,130,055 — Shares of common stock registered for resale (Represents the total shares available for sale by selling stockholders in the direct listing)
• 87% — Percentage of revenues from OneTest for Cancer (For the nine months ended September 30, 2025, indicating primary commercial focus)
• 85% — Percentage of revenues from OneTest for Cancer (For the year ended December 31, 2024, showing significant growth from 65% in 2023)
• 0% — Percentage of revenues from COVID-19 testing (For the year ended December 31, 2024, down from 18% in 2023, indicating business shift)
• 9% — Percentage of revenues from BioCheck (For the nine months ended September 30, 2025)
• 4% — Percentage of revenues from CLIAx (For the nine months ended September 30, 2025)
• 1,000 — Number of soldiers, sailors, airmen, and marines screened by HunterSeven Foundation (Using OneTest for Cancer in 2025, leading to identification of at least 18 cancers)
• 18 — Number of cancers identified by OneTest for Cancer (Among 1,000 veterans screened by HunterSeven Foundation in 2025)

Key Players & Entities

• 20/20 Biolabs, Inc. (company) — Registrant for S-1 filing
• Jonathan Cohen (person) — Chief Executive Officer of 20/20 Biolabs, Inc.
• Louis A. Bevilacqua, Esq. (person) — Legal counsel from Bevilacqua PLLC
• Nasdaq Capital Market (regulator) — Proposed listing exchange for AIDX common stock
• Maxim Group LLC (company) — Financial advisor for the direct listing price-setting mechanism
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1 filing
• U.S. National Cancer Institute (company) — Conducted blinded validation study for OneTest Premium in 2024
• Grail (company) — Competitor with Galleri test
• Vincere Cancer Center (company) — Cancer center whose Dr. Vershalee Shukla presented on MCEDs
• HunterSeven Foundation (company) — Veteran-founded organization using OneTest for Cancer for screenings

FAQ

Risk Factors

• CLIA and CAP Compliance [high — regulatory]: The company operates a CLIA-licensed and CAP-accredited laboratory. Failure to maintain these accreditations or comply with their stringent requirements could lead to suspension or revocation of licenses, significantly impacting operations and revenue generation.
• Competition in MCED Market [high — market]: The multi-cancer early detection (MCED) market is rapidly evolving and competitive. The success of OneTest for Cancer depends on its ability to demonstrate superior accuracy, clinical utility, and cost-effectiveness compared to existing and emerging diagnostic methods.
• Dependence on Key Technology [medium — operational]: The company's core products rely on proprietary AI algorithms and protein tumor marker (PTM) technology. Any disruption in the development, validation, or maintenance of these technologies could adversely affect product performance and market adoption.
• Path to Profitability [medium — financial]: As a company focused on developing and commercializing novel diagnostic tests, 20/20 Biolabs may incur significant research and development costs and may not achieve profitability for a considerable period. The success of the direct listing is crucial for funding ongoing operations and growth initiatives.
• FDA Approval Pathway [medium — regulatory]: While OneTest for Cancer is currently marketed as a laboratory-developed test (LDT), future expansion or claims may require FDA clearance or approval. Navigating the complex and evolving regulatory landscape for diagnostics, particularly for novel technologies, presents a significant risk.
• Reimbursement and Payer Acceptance [high — market]: Securing favorable reimbursement from payors for novel diagnostic tests like OneTest for Cancer is critical for widespread adoption. Lack of adequate reimbursement or challenges in demonstrating cost-effectiveness to payers could limit market penetration.
• Scalability of Laboratory Operations [medium — operational]: As the company aims to scale its testing volume, maintaining the quality and efficiency of its CLIA-licensed laboratory operations will be paramount. Any issues with scalability, quality control, or supply chain management could impact service delivery.
• Reliance on Existing Stockholders for Resale [low — financial]: The direct listing involves the resale of 15,130,055 shares by existing stockholders. The market's reception to these shares and potential selling pressure could impact the stock's valuation and liquidity.

Industry Context

The diagnostics industry, particularly in the realm of early disease detection, is characterized by rapid technological advancement and increasing competition. The multi-cancer early detection (MCED) segment, where 20/20 Biolabs operates with its OneTest for Cancer, is a high-growth area driven by the demand for less invasive and more effective screening methods. Key trends include the integration of artificial intelligence (AI) and machine learning into diagnostic platforms, and the development of blood-based tests utilizing novel biomarkers.

Regulatory Implications

Operating a CLIA-licensed and CAP-accredited laboratory subjects 20/20 Biolabs to rigorous quality control and operational standards. While currently marketing OneTest for Cancer as a Laboratory-Developed Test (LDT), future product expansions or claims may necessitate navigating the FDA's regulatory pathways, which can be complex and time-consuming for novel diagnostic technologies.

What Investors Should Do

1. Evaluate the competitive landscape and differentiation of OneTest for Cancer.
2. Analyze the path to reimbursement and payer adoption.
3. Assess the scalability and operational readiness of the laboratory.
4. Monitor the development and launch of OneTest for Longevity.
5. Understand the implications of a direct listing.

Key Dates

• 2023-12-31: Year-end financial reporting — Indicated OneTest for Cancer revenue at 65% of total revenue, with COVID-19 testing at 18%.
• 2024-12-31: Year-end financial reporting — Showed a significant shift with OneTest for Cancer revenue at 85% and COVID-19 testing revenue at 0%.
• 2025-09-30: Nine-month financial reporting — Further solidified OneTest for Cancer's dominance at 87% of revenues, with BioCheck at 9% and CLIAx at 4%.
• 2025: HunterSeven Foundation screening — 1,000 soldiers, sailors, airmen, and marines were screened using OneTest for Cancer, identifying at least 18 cancers, demonstrating clinical utility in a specific population.
• 2026-01-01: Expected launch of OneTest for Longevity — Marks the introduction of a new product line focused on inflammatory biomarkers, diversifying the company's offerings beyond cancer detection.

Glossary

Direct Listing

A method for a private company to become publicly traded by selling existing shares to the public, rather than issuing new shares to raise capital. (20/20 Biolabs is pursuing a direct listing, meaning existing stockholders will sell their shares, and the company itself is not raising new capital through this offering.)

S-1 Filing

The initial registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This document provides comprehensive information about the company's business, financials, risks, and the securities being offered.)

Nasdaq

A global electronic marketplace for buying and selling securities. (The company intends to list its shares on the Nasdaq stock exchange, which is a major venue for technology and biotech companies.)

CLIA

Clinical Laboratory Improvement Amendments. A U.S. federal regulatory standards that apply to all clinical laboratory testing performed on humans in the United States. (The company operates a CLIA-licensed laboratory, which is essential for performing diagnostic tests and is a key regulatory requirement.)

CAP

College of American Pathologists. An organization that accredits clinical laboratories. (The company's laboratory is CAP-accredited, indicating adherence to high standards of quality and performance in laboratory testing.)

MCED

Multi-Cancer Early Detection. Tests designed to detect multiple types of cancer from a single biological sample, typically blood. (The company's flagship product, OneTest for Cancer, is an MCED test, positioning it in a rapidly growing and important segment of cancer diagnostics.)

Protein Tumor Markers (PTMs)

Specific proteins found in the blood that can indicate the presence of cancer, often at early stages. (These are the biological signals that 20/20 Biolabs' OneTest for Cancer utilizes in conjunction with AI for detection.)

Laboratory-Developed Test (LDT)

A diagnostic test that is developed, validated, and performed within a single laboratory. (OneTest for Cancer is currently marketed as an LDT, which has a different regulatory pathway than FDA-approved diagnostic kits.)

Year-Over-Year Comparison

The S-1 filing for 20/20 Biolabs indicates a significant strategic pivot and growth in its core business compared to prior periods. Revenue concentration has dramatically shifted towards its flagship OneTest for Cancer, which grew from 65% of revenues in 2023 to 85% in 2024 and 87% in the first nine months of 2025. Concurrently, COVID-19 testing revenue has been eliminated, demonstrating a successful transition away from pandemic-related services. While specific financial metrics like revenue totals, net income, and margins are not detailed in this excerpt, the revenue breakdown clearly shows a strong focus and growth in the MCED segment, alongside the introduction of new product lines like OneTest for Longevity expected in 2026.

Key Financial Figures

• $200 — available at a starting price of under $200, (ii) can be accessed at home without p
• $323,414 — sed significantly in recent years, from $323,414 in 2022 to $1,490,881 in 2024. For the
• $1,490,881 — recent years, from $323,414 in 2022 to $1,490,881 in 2024. For the nine months ended Sept
• $1,305,286 — 30, 2025, sales of OneTest amounted to $1,305,286. We sell to employers, medical practiti
• $5 million — New Hampshire’s program provides $5 million in funding over two years and Maryland
• $1 million — ram for multi-cancer screening tests to $1 million for their fiscal year beginning July 20
• $400,000 — ir fiscal year beginning July 2025 from $400,000 in the prior year (typically, more than
• $700 million — was reintroduced in Congress to provide $700 million in federal funding (through the Federal

Filing Documents

• ea0269214-s1_2020bio.htm (S-1) — 1951KB
• ea026921401ex10-7_2020bio.htm (EX-10.7) — 25KB
• ea026921401ex10-14_2020bio.htm (EX-10.14) — 98KB
• ea026921401ex23-1_2020bio.htm (EX-23.1) — 2KB
• ea026921401ex-fee_2020bio.htm (EX-FILING FEES) — 45KB
• image_001.jpg (GRAPHIC) — 8KB
• image_002.jpg (GRAPHIC) — 47KB
• image_003.jpg (GRAPHIC) — 15KB
• image_004.jpg (GRAPHIC) — 13KB
• image_005.jpg (GRAPHIC) — 15KB
• image_006.jpg (GRAPHIC) — 41KB
• image_007.jpg (GRAPHIC) — 57KB
• image_008.jpg (GRAPHIC) — 16KB
• image_009.jpg (GRAPHIC) — 55KB
• image_010.jpg (GRAPHIC) — 76KB
• image_011.jpg (GRAPHIC) — 31KB
• 0001213900-25-121285.txt ( ) — 2822KB
• ea026921401ex-fee_2020bio_htm.xml (XML) — 24KB

Business

Business 50 Management 71 Executive Compensation 77 Certain Relationships and Related Party Transactions 81 Principal and Selling Stockholders 82 Description of Capital Stock 85 Shares Eligible for Future Sale 88 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 89 Plan of Distribution 92 Legal Matters 94 Experts 94 Where You Can Find More Information 94 Financial F-1 You should rely only on the information that we have provided in this prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any related free writing prospectus is accurate only as of the date on the front of this prospectus or any such related free writing prospectus, regardless of the time of delivery of this prospectus or any related free writing prospectus, or any sale of a security. INDUSTRY AND MARKET DATA We are responsible for the disclosure in this prospectus. However, this prospectus includes industry data that we obtained from market research, publicly available information and industry publications. We did not fund and are not otherwise affiliated with any of the sources cited in this prospectus. The market research, publicly available information and industry publications that we use generally state that the information contained therein has been obtained from sources believed to be reliable. The inform

View Full Filing

View this S-1 filing on SEC EDGAR